SCHEMBL2185142

SCHEMBL2185142

N#Cc1cc(C(=O)O)cc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM2B Q8NHM5 2/20 0.51
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
KDM4E B2RXH2 1/20 0.47
CYP1A2 P05177 1/20 0.47
GLA P06280 1/20 0.47
CYP2C19 P33261 1/20 0.47
HSD17B10 Q99714 1/20 0.47
PTPN1 P18031 1/20 0.45
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
XDH P47989 1/20 0.42
SLC22A12 Q96S37 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIN2C Q14957 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28505052 0.85 KDM2B (0.50) KDM2BMEN1KMT2AALDH1A1HPGD
SCHEMBL9670306 0.84 MEN1 (0.48) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL28747355 0.84 MEN1 (0.53) KDM2BMEN1KMT2AALDH1A1HPGD
SCHEMBL2185509 0.83 ESR1 (0.50) XDHSLC22A12
SCHEMBL688832 0.83 MEN1 (0.47) KDM2BMEN1KMT2AALDH1A1HPGD
SCHEMBL30714843 0.83 SLC22A12 (0.46) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL31525283 0.81 PTPN1 (0.60) MEN1KMT2AALDH1A1HPGDPTPN1
SCHEMBL4848179 0.81 PTPN1 (0.60) MEN1KMT2AALDH1A1HPGDPTPN1
Hydrochloric Acid SCHEMBL4848001 0.80 PTPN1 (0.58) MEN1KMT2AALDH1A1HPGDPTPN1
SCHEMBL9301557 0.80 ESR1 (0.43) MEN1KMT2ACA1CA2XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2343279-B1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME KISSEI PHARMACEUTICAL (JP) 2018-02-28 EP disclosed
US-8263622-B2 Fused-ring derivative and medical application of same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-09-11 US disclosed
US-20110207935-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-08-25 US disclosed
EP-2343279-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME Kissei Pharmaceutical Co., Ltd. (JP) 2011-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207935-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME XDH, OAT, PON1 KDM2B 3588/4885MEN1 1851/4885KMT2A 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.